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Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) strains are known for their emergent 
multi-drug resistance phenotypes, implication in nosocomial infections and outbreaks 
worldwide, being commonly associated with hospital-acquired MRSA (HA-MRSA) and 
community-acquired MRSA (CA-MRSA) skin and soft tissue infections. S. aureus causes 
a wide spectrum of clinical symptoms, ranging from mild to life-threatening diseases; 
disease severity is determined by microorganism-related virulence factors and host con-
dition. The ability of these strains to form microbial biofilms, one of the main pathogenic-
ity factors, generates difficult medical problems, favored by the widespread use of large 
invasive medical procedures (probes, catheters, heart valves, prostheses). Contamination 
of these devices is associated with the risk of subsequent development of human infec-
tions. The knowledge of virulence and antibiotic resistance patterns of HA-MRSA and 
CA-MRSA and encoding genes are very important for supporting effective infection con-
trol measures and therapy of staphylococcal infections.
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1. Introduction
Staphylococci are commensal bacteria that form part of microbiota of human and animal skin and 
mucous membranes. Among more than 40 species of the genus, Staphylococcus aureus is coloniz-
ing the nostrils and skin of ~30% of the population [1, 2]. S. aureus is an opportunistic pathogen, 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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causing infections when it crosses the barriers of natural defense and escapes the mechanisms 
of anti-infectious protection. Factors favoring staphylococcal infections include local (lesions of 
the skin, the presence of implants, catheters, etc.) and general (innate or acquired deficiencies of 
the immune system such as complement system deficiencies, granulocytopenia, agranulocyto-
sis, AIDS, diabetes, immunosuppressive treatments, etc.). It is able to cause a plethora of com-
munity (CA) and health care (HA) infections, ranging from superficial skin infections to severe, 
and potentially fatal, invasive diseases [3–5] due to its ability to produce a spectrum of virulence 
factors and resistance to multiple antibiotics, frequently encoded by mobile genetic elements 
(MGEs) [6], which have eased the persistence of S. aureus in hospital environment [7]. S. aureus 
is causing skin and soft tissue infections (SSTIs), endovascular infections, pneumonia, septic 
arthritis, endocarditis, osteomyelitis, foreign-body infections, and sepsis [8]. S. aureus is the most 
commonly isolated bacteria from wound infections and studies involving patients with chronic 
venous leg ulcers found S. aureus positive cultures in 88–93.5% of infections [9]. Bacteremia 
caused by S. aureus is associated with higher morbidity and mortality, compared with bactere-
mia caused by other pathogens, with an annual incidence rate of 20–50 cases/100,000 population, 
and a mortality rate of 10 and 30%. The highest mortality rates occur in patients with primary 
bacteremic pulmonary infections and infective endocarditis, whereas the lowest rates occur in 
patients with central or peripheral venous catheter-related infections [10]. The major concern 
refers mainly to methicillin-resistant S. aureus (MRSA) isolates. Health care-associated MRSA 
(HA-MRSA) are represented by the S. aureus strains isolated from patients after a hospitalization 
of two or more days or with the MRSA risk factors (history of recent hospitalization, surgery, 
dialysis, catheters, etc.). Community-associated MRSA (CA-MRSA) are those S. aureus isolates 
obtained from patients within 2 days of hospitalization and without the above-mentioned MRSA 
risk factors [11]. Infections by CA-MRSA isolates are usually associated with children, young 
age, recurrent infections and the use of injectable drugs [12].
In this chapter, we review some aspects related to resistance and virulence features in CA-MRSA 
and HA-MRSA strains, underlying the evolution of the highly successful community- and 
health care-associated lineages and their plasticity in ability to adapt to environmental changes.
2. Staphylococcus aureus resistance to antibiotics
Antistaphylococcal antibiotics are mainly targeting cell wall synthesis, proteins and nucleic 
acid synthesis, and different metabolic pathways. The large use of antibiotics, not only in the 
medical field but also in the agriculture has facilitated the evolution and spread of resistance 
genes [13]. Bacterial resistance can be constitutive (mutations of the target genes, efflux pumps 
overexpression, etc.) or acquired by horizontal gene transfer via various mobile genetic ele-
ments like plasmids, transposons, bacteriophages, pathogenicity islands, and staphylococcal 
cassette chromosomes [14]. Plasmids and staphylococcal cassette chromosomes in particular 
have played a central role in conferring resistance to β-lactam antibiotics and vancomycin [15].
Penicillin resistance is conferred by β-lactamase, an extracellular enzyme encoded by blaZ 
that is active when bacteria are exposed to β-lactam antibiotics. The enzyme acts on β-lactam 
ring by opening it through hydrolization [16].
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Methicillin resistance requires the presence of the chromosomally localized mecA gene. The 
mecA gene and its regulatory elements, form the mec complex: SCCmec elements carry the 
mecR1 and mecI genes, which regulate the expression of mecA, with increased mecA translation 
induced by β-lactam antibiotic exposure. SCCmec elements can also carry resistance genes 
for other antibiotics and heavy metals as well as the psm-mec locus, which encodes cytolysin 
termed phenol-soluble modulin-mec (PSM-mec) [16].
PBPs are membrane-bound enzymes that are used in cross-linkage of peptidoglycan chains 
by catalyzing the transpeptidation reaction [17]. PBP2a has a low affinity for β-lactam anti-
biotics and thus methicillin resistance also grants resistance to all β-lactam antibiotics [16].
Eleven types of SCCmec have been described, distinguished by the type of ccr gene complex 
that mediates the site-specific excision and insertion of the SCCmec cassette out of or into the 
bacterial genome and the class of mec complex that they bear [18].
There have been revealed molecular differences between CA-MRSA and HA-MRSA strains 
regarding the types of SCCmec: HA-MRSA strains carry the large staphylococcal chromosomal 
cassette mec (SCCmec) belonging to type I–III and containing the mecA gene, mostly universal 
among MRSA isolates and usually are resistant to several classes of non-β-lactam antibiotics. It 
seems that the large SCCmec types I–III are present in HA-MRSA strains and were transferred 
to S. aureus from a commensal staphylococcal species [19]. Carriage of the psm-mec locus from 
type II SCCmec elements attenuates virulence, suppresses colony spreading activity, reduces 
expression of the chromosomally encoded PSMa, and promotes biofilm formation [20].
HA-MRSA strains seldom carry the genes for the Panton-Valentine leukocidin (PVL). CA-MRSA 
isolates carry smaller SCCmec elements, most commonly SCCmec type IV or type V [21]. 
CA-MRSA strains are resistant to fewer non-β-lactam classes of antibiotics and frequently carry 
PVL genes. There has been suggested that the smaller SCCmec types IV, V, VI, and VII have 
been transferred to methicillin-susceptible backgrounds [21, 22]. One study suggested that the 
type IV SCCmec element has been transferred to an MSSA strain [23]. The type IV SCCmec was 
originally associated with MRSA infections in patients with no HA-MRSA risk factors [21].
There have been revealed that the deletion of the gene encoding PBP 4 in two common 
CA-MRSA isolates, USA300 and USA400, resulted in a 16-fold reduction in oxacillin and naf-
cillin resistance in these particular stains. These studies suggest that PBP 4 is a significant 
target for the discovery of agents effective against CA-MRSA [24].
There have been also reported CA-MRSA strains positive for mecA and PBP 2a that were 
phenotypically oxacillin susceptible [25]. It was therefore suggested that mecA expression 
alone does not appear to be sufficient to guarantee phenotypic methicillin resistance, and 
that the existence of additional molecular targets could be associated with the susceptibility 
of oxacillin in certain strains and the involvement of genes different from the known effectors 
of methicillin resistance in CA-MRSA. The vraS/vraR two-component regulatory system is 
required for oxacillin resistance in CA-MRSA [26, 27].
The emergence/re-emergence of successful S. aureus clones suggests a rapid bacterial adap-
tion and evolution, which includes the emergence of antibiotic resistance and increased viru-
lence and/or transmissibility.
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Most of the nosocomial MRSA infections are caused by five major lineages that circulate inter-
nationally: CC5, CC8, CC22, CC45 and CC30 [28].
ST1 pulsotype USA 400—represented the most frequently CA-MRSA clone in the United 
States after 1990s; was characterized by carrying SCCmec type IV that has been usually suscep-
tible to most non-β-lactam antibiotics and cause SSTIs. This strain lacked PVL genes and circu-
lates in the community in Australia (WA-MRSA-1) and England [18, 29]. ST80 is PVL+-bearing 
SCCmec type IV and have been reported in several Western European countries such as Austria, 
Norway, Denmark, Sweden, England, Switzerland, Greece and France [18]. ST30 corresponds 
to phage type 80/81 nosocomial strain of S. aureus from United States during the 1950s and 
1960s. These strains were MSSA strains that carried the PVL genes [30] and the SCCmec type 
IV element. ST59 strains are PVL+, they have diverse spa types and several SCCmec types were 
isolated from different countries worldwide like: Taiwan, Australia, Denmark, Netherlands 
England, and the United States [18]. In Taiwan, ST59 clones with a multidrug-resistant phe-
notype are the most encountered, having a distinctive SCCmec DNA sequence [31]. ST93 was 
first identified in 2000 in Queensland and New South Wales, Australia. It spread rapidly to 
become the predominant PVL+ MRSA clone isolated from infections in those regions. USA300 
Strains has the following characteristics: the carriage of SCCmec type IV, PVL genes, and, in 
most strains, the ACME element. USA300 is classified as ST8 by MLST and is usually clas-
sified as t008 by spa typing. It is frequently susceptible to several non-β-lactam antibiotics 
and became the dominant CA-MRSA strains in the United States, has been also identified in 
Western Europe [18], Japan [32] and Australia, where it has been called WA-MRSA-12 [18, 33].
MRSA infections in the community can also be caused by livestock-associated MRSA (LA-MRSA). 
LA-MRSA is initially associated with livestock and differs from genotypic HA-MRSA and geno-
typic CA-MRSA in its genomic traits. CC9 clonal complex (LA-MRSA) is most frequent among 
livestock in Asia [34]. In the USA, ST5 (MRSA) was isolated from pigs [35]. CC1 (MRSA) is 
prevalent in Romanian nosocomial infections and has low host specificity [36].
The quinolones act on DNA gyrase, which relieves DNA supercoiling, and topoisomerase IV, 
which separates concatenated DNA strands. Resistance to quinolones results from the step-
wise acquisition of chromosomal mutations [16]. Quinolone affinity is reduced by changes 
of the amino acids in the enzyme-DNA complex (quinolone resistance-determining region 
[QRDR]). The most common sites of resistance mutations are GyrA subunit in gyrase and 
ParC (GrlA in S. aureus) of topoisomerase IV. Drugs primarily target topoisomerase IV and 
the mutations at this level are essential for resistance [37, 38]. The confluence of high bacterial 
density, especially inside biofilms, the likely preexistence of resistant subpopulations, and 
the sometimes limited quinolone concentrations achieved at sites of staphylococcal infections 
creates an environment that fosters selection of resistant mutants [37].
An additional mechanism of resistance in S. aureus is induction of the NorA multidrug-resis-
tance efflux pump with increased expression can result in low-level quinolone resistance [39].
S. aureus response to vancomycin inhibitory activity divides the strains into sensitive, inter-
mediate and resistant. Vancomycin intermediate-resistant S. aureus (VISA) have MICs to 
vancomycin of 8–16 μg/ml (MIC = 4–8 μg/ml). There has been identified the existence of a pre-
VISA stage of resistance known as heterogeneous VISA (hVISA) [16]. An hVISA phenotype 
Staphylococcus Aureus94
refers to a mixed cell population—derived originally from a single colony of S. aureus—in 
which the majority of cells have little or no resistance to vancomycin (MIC ≤ 2 μg/ml) and a 
sub-population of cells is resistant to the antibiotic at the level of VISA (MIC ≥ 4 μg/ml) [40].
The molecular mechanisms that underlie development of hVISA are incompletely defined. 
Fundamental characteristics of the VISA phenotype include increased cell wall thickness, 
caused by differentially regulated cell wall biosynthesis and stimulatory pathways [15, 41], 
reduced cross-linking of peptidoglycan, decreased autolytic activity of the enzymes responsi-
ble to cell-wall turnover [15, 42], altered surface protein profile, dysfunction of the agr system 
and changes to growth characteristics [15, 43].
Molecular basis of the VISA phenotype is not fully understood but several genes/mutations are 
known to contribute to its development. The mutations within genes encoding two-component 
regulatory systems, such as graRS and walKR are of particular significance. GraRS differentially 
regulates transcription of cell wall biosynthesis genes and has been associated with a broad array 
of genes and regulators that play a role in the intermediate resistance phenotype [44]; GraRS also 
up-regulates genes in the capsule biosynthesis operon, leading to increased capsule production 
[44]. GraRS up-regulates the dlt operon and the mprF/fmtC genes, which are linked to teichoic acid 
alanylation and alteration of cell wall charge [15]. Point mutations within graRS reduced suscepti-
bility to vancomycin [15, 45] and graRS mutations are linked to modified expression of global regu-
lators, rot and agr [15, 44]. rpoB a gene encoding the DNA-dependent RNA polymerase β-subunit 
is commonly associated with increased resistance to vancomycin, prolonged propagation time 
and increased cell wall thickness [15, 46]. VISA isolates have been shown to have non-silent muta-
tions in vraSR. Such mutations could lead to downstream up-regulation of over 40 cell wall synthe-
sis genes, including genes required for producing cell wall derivatives such as D-Ala-D-Ala [15].
The VISA strains produce considerable amounts of peptidoglycan and this generates thicker, 
irregularly shaped cell walls. They also expose more D-Ala-D-Ala residues available to bind 
and trap vancomycin which acts as a further impediment to drug molecules reaching their 
target on the cytoplasmic membrane [16].
Complete vancomycin resistance in S. aureus (MIC ≥16 μg/ml) is conferred by the vanA operon 
(containing vanA, vanH, vanX, vanS, vanR, vanY and vanZ genes) encoded on transposon 
Tn1546, originally a part of a vancomycin-resistant enterococci (VRE) conjugative plasmid 
[15, 47]. The vanA operon is controlled via a two-component sensor-regulator system encoded 
by vanS and vanR that sense vancomycin and activate transcription of the operon, respec-
tively, VanA, VanH and VanX together are essential for the vancomycin resistance phenotype. 
S. aureus can acquire enterococcal plasmids during discrete conjugation events. Vancomycin 
resistance in S. aureus is maintained by retaining an original enterococcal plasmid or by a 
transposition of Tn1546 from the VRE plasmid into a staphylococcal resident plasmid [15, 48].
3. Staphylococcus aureus adhesion and biofilm development
The broad range of infections caused by S. aureus is related to a number of virulence factors 
that allow it to adhere to surface, invade or avoid the immune system and cause harmful toxic 
effects to the host [49].
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The initialization of the colonization process is started by the attachment of S. aureus to the 
host cell surface through adhesins. Proteins covalently anchored to cell peptidoglycans repre-
sent one major class of S. aureus adhesins, which attach to the extracellular matrix or plasma 
components via a threonine residue and are known as the microbial surface component rec-
ognizing adhesive matrix molecules (MSCRAMMs) [49].
Staphylococcal cell wall-anchored (CWA) proteins are secreted by the Sec system and share 
a C-terminal cell wall anchoring motif, hydrophobic domain and positively charged domain 
[50]. Foster et al. [50] proposed to classify the Staphylococcal CWA proteins into four groups 
based on structural motifs: MSCRAMMs (microbial surface component recognizing adhe-
sive matrix molecules), the NEAT motif family, the three-helical bundle family and the G5-E 
repeat family. All of these types of CWA proteins are involved in staphylococcal biofilm 
formation. MSCRAMMs are adhesins that contain at least two IgG-like folds and employ a 
ligand binding mechanism called dock, lock and latch [50]. MSCRAMMS are composed of a 
binding domain, a cell wall spanning domain and a domain for the covalent or non-covalent 
attachment. These adhesins can bind one or more human proteins (collagen—mostly via Cna, 
fibronectin—via FnbAB, fibrinogen—via ClfAB and Fib) [51, 52].
The Staphylococcal MSCRAMMs are the Clf-Sdr family proteins, including bone sialoprotein-
binding protein (Bbp), the fibronectin-binding proteins (FnBPs) and collagen adhesion (CNA) 
[53]. The Clf-Sdr family consists of Clumping factor A (ClfA), clumping factor B (ClfB) and 
the Sdr proteins. ClfA and ClfB are fibrinogen-binding proteins in S. aureus [50, 53]. Rot and 
agr affect bacterial binding to fibrinogen by regulating clfB but not clfA [54]. S. aureus has two 
fibronectin-binding proteins, FnBPA and FnBPB, encoded by fnbA and fnbB, respectively. 
FnBP binding to fibronectin induces bacterial invasion into epithelial cells, endothelial cells 
and keratinocytes [53]. The FnBPs affect biofilm formation by a self-association mechanism 
that is distinct from ligand binding and virulence [55, 56].
The NEAT motif family consists of the iron-regulated surface determinant (Isd) proteins who 
bind heme or hemoglobin, facilitating its transport into the bacterial cell, and they are up-
regulated in iron-limiting conditions [57]. S. aureus IsdA is the most abundant CWA protein in 
iron starvation conditions, and also decreases surface hydrophobicity, which makes S. aureus 
more resistant to bactericidal fatty acids and peptides in human skin. IsdA also is able to bind 
human fibrinogen and fibronectin [53].
The sole three-helical bundle cell wall-anchored protein is Staphylococcal Protein A (SpA), which 
is present in all strains of S. aureus. SpA allows immune evasion by binding to the conserved 
Fc region of immunoglobulin IgG, and contributes to disruption of the host immune response 
by promoting bacterial survival in human blood after being released from the cell wall [53, 58].
G5-E Repeat Family: Aap/SasG—G5-E repeats are found in cell wall-anchored adhesins in 
Gram-positive organisms (are named after the five conserved glycine residues in each repeat). 
S. aureus SasG promotes attachment to human desquamated nasal epithelial cells via it’s A 
domain [59]. Multiple studies have shown that the G5-E repeats of SasG and Aap are able 
to dimerize by binding to Zn2+, forming a “twisted rope” structure [53, 60]. This property is 
thought to enable intercellular adhesion when adjacent SasG or Aap proteins dimerize via 
their G5-E domains.
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Uncategorized CWA Proteins—the remaining uncategorized cell wall-anchored proteins are 
Bap and several Sas proteins, including SasA/SraP. SasX is another cell wall-anchored adhesin 
that has been shown to play an important role in virulence [53].
Surface-associated proteinaceous adhesins—autolysins AtlA and AtlE are found in S. aureus 
involved in cell wall turnover, cell division and cell lysis [53], they attach to extracellular 
matrix materials and can augment the biofilm matrix with eDNA by inducing cell lysis.
Non-proteinaceous surface-associated adhesins—wall teichoic acids and lipoteichoic acids 
have been shown to play a role in adhesion, colonization of host cells and biofilm formation. 
Wall teichoic acids are covalently linked to the peptidoglycan and consist of alternating phos-
phate and ribitol, while lipoteichoic acids attach to the outer leaflet of the cell membrane and 
have alternating phosphate and glycerol [61].
The polysaccharide intercellular adhesion (PIA) is a secreted polysaccharide that is synthe-
sized by the ica operon and has been thoroughly studied in the context of biofilm formation, 
immune evasion, and pathogenesis. PIA is a glycan of β-1,6-linked 2-acetamido-2-deoxy-D-
glucopyranosyl residues with a net positive charge that promotes intercellular aggregation 
and attachment of cells to inert surfaces. The ica operon consists of four biosynthesis genes 
such as icaA, icaD, icaB and icaC and a divergently transcribed repressor, icaR. Carriage of the 
ica locus is a characteristic of most clinical S. aureus strains [62].
One of the reasons the staphylococcal infections are difficult to eradicate is the bacteria’s abil-
ity to develop community structures known as biofilms by attaching to different surfaces (tis-
sues, catheters and medical devices), and often occur in areas of the body that are not easily 
accessible for treatment [63].
Biofilm is an assemblage of microbial cells that are irreversibly associated to a surface and 
embedded in a protective extracellular polymeric matrix. Biofilm-associated organisms have 
proteins production and genes expression modification compared to their planktonic coun-
terparts [64].
Biofilm formation can be divided into three major stages: initial attachment, development/
maturation of the biofilm and dispersion.
During initial attachment, bacteria adhere to the available surface and in case of abiotic one its 
conditioning is important through various physiochemical parameters: chemical composition 
of the material, hydrophobicity, electrostatic charges, surface energy and surface roughness 
and in the case of biotic adhesion: serum and tissue protein adsorption [65].
The final stage of biofilm development is the detachment of cells from the biofilm colony 
and their dispersal into the environment, which contributes to biological dispersal, bacterial 
survival and disease transmission. Like other stages of biofilm development, dispersal is a 
complex process that involves numerous environmental signals, signal transduction path-
ways and effectors [66].
The biofilm matrix is a complex structure that contains extracellular DNA (eDNA), both from 
lysed bacteria and potentially from host neutrophil cell death [53], proteinaceous adhesins 
directly associated with bacteria in the biofilm or free in the biofilm matrix [67], recycled 
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cytoplasmic proteins that moonlight as components of the extracellular matrix [68], the extra-
cellular polysaccharide intercellular adhesin (PIA), teichoic acids [53]. The matrix can impede 
the access of certain types of immune defenses, such as macrophages [69].
Cell adhesion and subsequently biofilm formation are processes mediated by covalently and 
non-covalently cell wall proteins and non-protein factors. For S. aureus more than 20 adhesins 
were identified [53].
Switching between planktonic and biofilm-forming modes represents a major life style change 
for microbes, and has been shown to be a tightly regulated process [70] through quorum sens-
ing (QS) which is a cell-cell communication mechanism in which bacteria secrete and sense 
small diffusible molecules called autoinducers (AIs) to coordinate social activities, such as bio-
luminescence, biofilm formation, swarming behavior, antibiotic production and virulence factor 
secretion [71].
Staphylococcal biofilm formation is affected by growth conditions (e.g., NaCl, glucose, human 
plasma, etc.) and is controlled by multiple global regulators such as SarA, Agr, SigB and 
Sae. The Sae-regulon includes both the factors promoting biofilm formation (i.e., Coa, Emp, 
Eap, FnBPA, FnBPB, Hla and Hlb) and biofilm dispersal factors (nuclease and proteases) and 
depending on growth conditions and strain backgrounds, the Sae system could affect biofilm 
formation either positively or negatively [72].
Bacteria in biofilms can tolerate ten to thousand fold higher levels of antibiotics than the 
genetically equivalent planktonic bacteria. Staphylococcal biofilms cause biomaterial-asso-
ciated infections which do not respond to antimicrobial treatment often requiring removal 
of the same leading to substantial morbidity and mortality. It has also been observed that 
biofilms harbour persister cells and small colony variants [73], whereas planktonic persisters 
are eliminated by the immune system in vivo, persisters in biofilms serve as a shield evading 
the immune response and a reservoir of such shielded persisters is a potential source for the 
emergence of heritable antibiotic resistance [14].
4. Staphylococcus aureus soluble virulence factors
S. aureus secretes numerous exotoxins, including polypeptides that destroy the integrity of the 
host cell plasma membrane. These polypeptides are pore-forming toxins (PFT): α-hemolysin 
and the bi-component leukocidins γ-hemolysin, β-hemolysin, the Panton Valentine leukoci-
din (PVL), LukED, and LukGH/AB and phenol soluble modulins (PSMs) [74].
α-Hemolysin is the most characterized virulence factor of S. aureus. Upon binding to the cell 
surface, α-hemolysin forms pores that allow the transport of molecules such as K+ and Ca2+ 
ions, leading to necrotic death of the target cell.
S. aureus possesses several other PFTs in addition to α-hemolysin that for pore formation 
involves two polypeptides that have been named S (slow) and F (fast) based on their electro-
phoretic mobility. The PFTs include (i) γ-hemolysin corresponding to two combinations of a 
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S component (HlgA or HlgC) with a F component (HlgB); (ii) the PVL made of LukS-PV and 
LukF-PV; (iii) LukED and (iv) LukGH, also known as LukAB [74]
The γ hemolysin variant and leukocidin E-D gene, as well as other genes encoding exotoxins, 
were detected evenly in HA and CA-MRSA strains, while sec and sek genes were found only in 
CA-MRSA strains [75].
β-Hemolysin is a neutral sphingomyelinase, it hydrolyses a plasma membrane lipid—sphin-
gomyelin and does not form pores in the plasma cell. β-hemolysin’s enzymatic activity is 
required for its hemolytic activity [74].
δ-Hemolysin is a small amphipathic α-helix-structured peptide (26 AA). Its hemolytic activity 
can be realized by forming transmembrane pores, affecting the membrane curvature or acting 
as detergent to solubilize the membrane [76].
This family of cytotoxic peptides includes new peptides termed PSM. PSMs represent a 
secreted α-helical peptides produced by different Staphylococcus species. PSMs encoding 
genes are able to activate and lyse human neutrophils and are generated at high concen-
trations by CA-MRSA strains [77]. The psm-mec, was the first PSMs gene found within an 
SCCmec MGE and was linked to the class A mec gene complex present in SCCmec types II, III 
and VIII, with a conserved location next to the mecI gene [74, 78].
Protein A prevents the opsonization and phagocytosis by ineffectually binding the Fc region 
of IgG. It also initiates a proinflammatory cascade in the airway by activating tumor necrosis 
factor receptor 1 (TNFR1) and B cells in concert with other ligands. MRSA strains with certain 
spa types have a decreased ability to invade human cells in vitro, revealing an association with 
certain spa types and virulence [18].
S. aureus produces a group of toxins called the toxic shock syndrome toxin-1 (TSST-1) and 
enterotoxins (SEA, SEB, SECn, SED, SEE, SEG, SEH and SEI) and the exfoliative toxins A and 
B (involved in staphylococcal scalded skin syndrome). Cytolytic toxins form pores of holes 
called β-barrel pores in the plasma membrane. This leads to leakage of the cell’s content and 
lysis of the target cell [79].
PVL is a bi-component exotoxin transmitted by bacteriophages, encoded by two genes, 
lukF-PV and lukSPV. PVL genes are carried by CA-MRSA strains and in a small propor-
tion by clinical MSSA strains. Therefore PVL plays an important role in fitness, transmis-
sibility and virulence, but the role of PVL in the pathogenesis of CA-MRSA infections 
is not fully understood [80]. PVL genes are spreading among S. aureus strains by clonal 
expansion and horizontal transfer. There have been demonstrated that β-lactam antibiotics 
increased the production of PVL in vitro through transcriptional activation [81, 82]. PVL 
inserts itself into the host’s plasma membrane and forms a pore of a hole. PVL exhibits a 
high affinity toward leukocytes. PVL can inactivate mitochondria and induce apoptosis. 
In animal models, PVL has been shown to be dermonecrotic [18], perhaps explaining the 
pathobiology of the characteristic skin lesions associated with CA-MRSA SSTIs. That the 
presence/absence of PVL genes in MRSA strains did not interfere with strain virulence in 
mouse models of sepsis and SSTI, and their presence did not decrease neutrophil survival 
in in vitro assays [18].
Molecular Features of Virulence and Resistance Mechanisms in Nosocomial…
http://dx.doi.org/10.5772/intechopen.75191
99
α-Toxin lyses immune cells like macrophages and lymphocytes, alters platelet morphology, which 
increased thrombotic events associated with S. aureus sepsis [83]. The nucleases, proteases, lipases, 
hyaluronidase and collagenase convert local host tissue into nutrients required for bacterial growth.
Arginine catabolic mobile element (ACME) is a large MGE that plays an important role in the 
growth, transmission and pathogenesis of CA-MRSA. Two main gene clusters identified as 
arc genes (arcA, arcB, arcC and arcD) and the opp genes (opp-3A, opp-3B, opp-3C, opp3-D and 
opp3-E) are recognized to be virulence factors [84].
5. Regulation of virulence factors expression in Staphylococcus 
aureus
In S. aureus, virulence factors production is coordinated by different regulators, for example, 
DNA binding proteins (e.g., SarA and its homologues), two-component signaling systems 
(e.g., ArlRS, AgrAC, SaeRS and SrrAB) and alternative sigma factor B [72].
Among the regulatory elements, the Agr (the accessory gene regulator) system is the only 
characterized QS system in S. aureus and controls the expression of approximately 150 genes 
[85]. Agr system regulation depends on cell density. During initial stage of colonization, when 
there is a low cell density, the Agr QS system is expressed low, but when the biofilm reach 
maturation and the cell density is high, Agr activity increases and upregulates secreted viru-
lence factors. The agr regulation of the proteases is via Rot, whose transcriptional repression 
of the proteases is relieved when agr is induced [65, 86].
S. aureus produces AI-2 through the functional luxS gene it has. Due to the dual function of 
LuxS and the absence of genomic evidence of established AI-2 receptors, the AI-2 quorum-
sensing function in S. aureus has been intangible, until now [71].
Sigma B (SigB) is an alternative sigma factor of RNA polymerase that is activated in stress 
response and modifies gene expression. SigB upregulates the expression of different factors 
involved in initial stages of biofilm formation like coagulase, FnBPA and clumping factor [87]. 
It also controls negative factors that are associated with a planktonic phenotype and seeding 
dispersal, including enterotoxin B, cysteine protease (SplB), serine protease (SplA), the metal-
loprotease Aur, staphopain, leukotoxin D and β-hemolysin [53].
The sar (Staphylococcal accessory regulator) locus produces three transcripts from three sepa-
rate promoters, all of which contain the ORF for the DNA-binding protein SarA [53]. SarA 
also directly regulates several genes that affect biofilm formation. There have been demon-
strated that the mutation of sarA gene in the USA300 clone limits accumulation of α-toxin and 
PSMs through the increased production of extracellular proteases rather than from transcrip-
tion of the hla or agr genes [88].
6. Conclusions
Staphylococcus spp. are common residents of the normal human and animal microbiota, but in 
certain favoring conditions, they can surpass the anti-infectious defense barriers and become 
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opportunistic pathogens. Staphylococci can cause numerous types of infections some of them 
potentially fatal due to their numerous virulence factors, biofilm formation capacity and 
antibiotic resistance mechanisms. Taking into account the increased incidence and spread of 
MRSA and multiple-drug resistant strains, a better knowledge of the virulence and pathoge-
nicity mechanisms and of their relationships with resistance, as well as of the quorum sensing 
mechanisms is essential for the development of novel anti-staphylococcal strategies, targeting 
the expression of virulence factors or of their regulatory mechanisms.
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